The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Malaria medicines: a glass half full?
Abstract
Despite substantial scientific progress over the past two decades, malaria remains a worldwide burden that causes hundreds of thousands of deaths every year. New, affordable and safe drugs are required to overcome increasing resistance against artemisinin-based treatments, treat vulnerable populations, interrupt the parasite life cycle by blocking transmission to the vectors, prevent infection and target malaria species that transiently remain dormant in the liver. In this Review, we discuss how the antimalarial drug discovery pipeline has changed over the past 10 years, grouped by the various target compound or product profiles, to assess progress and gaps, and to recommend priorities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424
The economic and social burden of malaria
Sachs, J., & Malaney, P. (2002) · Nature · doi:10.1038/415680a · Cited by 2,248
Spread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205
A molecular marker of artemisinin-resistant Plasmodium falciparum malaria
Ariey, F., Witkowski, B., Amaratunga, C., Beghain, J., Langlois, A.-C., Khim, N., Kim, S., Duru, V., Bouchier, C., Ma, L., et al. (2014) · Nature · doi:10.1038/nature12876 · Cited by 2,090
Evidence of Artemisinin-Resistant Malaria in Western Cambodia
Noedl, H., Se, Y., Schaecher, K., Smith, B. L., Socheat, D., & Fukuda, M. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0805011 · Cited by 1,785
Insecticide-treated bed nets and curtains for preventing malaria
Lengeler, C. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000363.pub2 · Cited by 1,700
Doolan, D. L., Dobaño, C., & Baird, J. K. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00025-08 · Cited by 1,301
Spiroindolones, a Potent Compound Class for the Treatment of Malaria
Rottmann, M., McNamara, C., Yeung, B. K. S., Lee, M. C. S., Zou, B., Russell, B., Seitz, P., Plouffe, D. M., Dharia, N. V., Tan, J., et al. (2010) · Science · doi:10.1126/science.1193225 · Cited by 1,206
Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Türbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H. K., et al. (1999) · Science · doi:10.1126/science.285.5433.1573 · Cited by 1,173
Cited by
Phillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
Self-citationHit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Self-citationAshley, E. A., Pyae Phyo, A., & Woodrow, C. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30324-6 · Cited by 553
New developments in anti-malarial target candidate and product profiles
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R., Kaszubska, W., Macintyre, F., Mazzuri, S., Möhrle, J. J., & Wells, T. N. C. (2017) · Malaria Journal · doi:10.1186/s12936-016-1675-x · Cited by 520
Self-citationAntimalarial Drug Resistance: A Threat to Malaria Elimination
Menard, D., & Dondorp, A. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025619 · Cited by 499
Malaria eradication within a generation: ambitious, achievable, and necessary
Feachem, R. G. A., Chen, I., Akbari, O., Bertozzi-Villa, A., Bhatt, S., Binka, F., Boni, M. F., Buckee, C., Dieleman, J., Dondorp, A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31139-0 · Cited by 366
Artemisinin Action and Resistance in Plasmodium falciparum
Tilley, L., Straimer, J., Gnädig, N. F., Ralph, S. A., & Fidock, D. A. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2016.05.010 · Cited by 359
Veiga, M. I., Dhingra, S. K., Henrich, P. P., Straimer, J., Gnädig, N., Uhlemann, A.-C., Martin, R. E., Lehane, A. M., & Fidock, D. A. (2016) · Nature Communications · doi:10.1038/ncomms11553 · Cited by 335
Hemingway, J., Shretta, R., Wells, T. N. C., Bell, D., Djimdé, A. A., Achee, N., & Qi, G. (2016) · PLOS Biology · doi:10.1371/journal.pbio.1002380 · Cited by 293
Self-citation
Metadata
- Authors
- Wells, T. N. C., van Huijsduijnen, R. H., & Van Voorhis, W. C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-05-22
- Volume
- 14
- Issue
- 6
- Pages
- 424-442
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1771852563
- Cited by
- 430
- References
- 125
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.